Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

12 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Clinical response of metastatic gastric cancer patients to cisplatin and fluorouracil (CF) combination chemotherapy

ABSTRACT: This study was conducted to identify transcriptional profiles predictive of a clinical response of metastatic gastric cancer patients to cisplatin and fluorouracil (CF) combination chemotherapy. Endoscopic biopsy samples were collected from CF-treated metastatic gastric cancer patients prior to therapy and following the development of resistance to therapy.

ORGANISM(S): Homo sapiens

SUBMITTER: Jeffrey Green

PROVIDER: E-GEOD-14208 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Dysregulated genes associated with acquired resistance

Project description:This study was conducted to identify dysregulated genes associated with acquired resistance to chemotherapy. Endoscopic biopsy samples were collected from CF-treated metastatic gastric cancer patients prior to therapy and following the development of resistance to therapy.

2011-06-01 | E-GEOD-14209 | biostudies-arrayexpress

Expression data from human endoscopic biopsy samples

Project description:This SuperSeries is composed of the following subset Series: GSE14208: Clinical response of metastatic gastric cancer patients to cisplatin and fluorouracil (CF) combination chemotherapy GSE14209: Dysregulated genes associated with acquired resistance Refer to individual Series

2011-06-01 | E-GEOD-14210 | biostudies-arrayexpress

Clinical response of metastatic gastric cancer patients to cisplatin and fluorouracil (CF) combination chemotherapy

Project description:This study was conducted to identify transcriptional profiles predictive of a clinical response of metastatic gastric cancer patients to cisplatin and fluorouracil (CF) combination chemotherapy.

2011-06-01 | GSE14208 | GEO

Gastric cancer: cancer vs. normal, chemoresistance signature that correlates with time to progression of disease

Project description:microRNA profiling of gastric cancer vs. normal, pre-/-post CF (cisplatin/fluorouracil) chemotherapy. Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. At the time of disease progression, post-treatment samples were collected from 8 clinical responders. miRNA expression was determined using a custom-designed Agilent microarray. In order to identify an miRNA signature for chemotherapy resistance, we correlated miRNA expression levels with the time to progression (TTP) after CF. 90 pre-treatment gastric cancer samples, 34 healthy volunteers, 8 post-treatment samples.

2011-12-16 | E-GEOD-30070 | biostudies-arrayexpress

Gastric cancer: cancer vs. normal, chemoresistance signature that correlates with time to progression of disease

2011-12-16 | GSE30070 | GEO

Homo sapiens

Project description:Clinical response of metastatic gastric cancer patients to cisplatin and fluorouracil (CF) combination chemotherapy

| PRJNA114459 | ENA

The genes associated with the response to S-1,cisplatin and docetaxel combination chemotherapy (DCS therapy) for metastatic gastric cancer:

Project description:Despite the effort in defining the molecular mechanisms for the drug resistance, predictors of response to chemotherapy have yet to be developed in gastric cancer. With microarray of whole human genes, we determined 29 genes associated with the response to cisplatin and docetaxel combination chemotherapy for metastatic gastric cancer. We obtained Fresh-frozen samples of tumor tissue and background gastric mucosa tissue from 19 patients with gastric cancer by endoscopic biopsy before DCS therapy. Total RNA was extracted from individual microdissected populations of cancer cells and background mucosa cells using RNAeasy mini kits and amplified with a random primer, WT-Ovation FFPE RNA Amplification System V2; NuGEN, Cincinnati, Ohio) according to the manufacturer’s protocols. The amplified fragmented RNA was hybridized on a Whole Human Genome Oligo Microarray Chip (Agilent Technologies) containing 44,000 cDNA clones.

2014-08-31 | E-GEOD-31811 | biostudies-arrayexpress

Gene expression in CF-vs-non CF human airway epithelial cell samples obtained by nasal brushing.

Project description:A small-scale whole genome microarray study of gene expression in human native nasal epithelial cells from F508del-CFTR homozygous CF patients and non-CF controls. We used the custom designed Affymetrix HsAirwaya520108F Arrays to compare gene expression in 5 CF and 5 non CF nasal epithelial cell samples. We analysed a total of 10 samples (5 CF and 5 non CF). The CF group contained 2 males and 3 females, with an average age of 14 years and an average of 6% inflammatory cells per sample, and the non CF group contained 3 males and 2 females with an average age of 14.8 years and an average of 4.7% inflammatory cells.

2013-04-10 | E-GEOD-40445 | biostudies-arrayexpress

Gene expression in CF-vs-non CF human airway epithelial cell samples obtained by nasal brushing.

2013-04-10 | GSE40445 | GEO

Transcription profiling of human nasal brushing cells from 19 cystic fibrosis (CF) patients and 19 healthy controls

Project description:We have compared gene expression in human nasal brushing cells from 19 cystic fibrosis (CF) patients and 19 healthy controls using a 5.2K cDNA microarray. Our aim is to identify new disease biomarkers for the Cystic Fibrosis Gene Therapy Consortium. These markers will be used to report more effectively on the response to the administration of gene therapy in vivo. Cystic Fibrosis is a recessive genetic disease caused by mutations in the cystic fibrosis conductance regulator (CFTR) gene which encodes a chloride ion channel. The most common mutation is the ∆F508 mutation, present on 70% of CF chromosomes in Caucasian populations. The disease affects many organs in the body such as the pancreas, liver, sweat glands, small intestine and reproductive tracts but is most commonly associated with progressive, inflammatory lung disease. The current average life expectancy of CF patients is 35 years. Gene therapy is being developed as a treatment for CF airway disease, however, means of measuring the efficiency and efficacy of gene therapy in vivo are lacking. This is mainly due to the difficulty in measuring the chloride conductance of CFTR in cells and tissues. Furthermore, clinical assays for measuring improvements in lung function are insensitive. Surrogate markers of inflammation and CFTR function will therefore be important for the effective assessment of gene therapy in vivo. We have analysed gene expression in human nasal epithelium as this is considered an accessible surrogate for the conducting airways where disease manifests in the majority of patients. Additionally, this tissue will be sampled in clinical trials.

2011-04-30 | E-MEXP-436 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data